Raily Aesthetic Medicine International Holdings Limited (HK:2135)
:2135
Want to see HK:2135 full AI Analyst Report?
2135 Stock Chart & Stats
HK$0.17
<HK$0.01(0.99%)
At close: 4:00 PM EST
HK$0.17
<HK$0.01(0.99%)
Day’s Range― - ―
52-Week RangeHK$0.11 - HK$0.20
Previous CloseN/A
Volume240.00K
Average Volume (3M)289.64K
Market Cap
HK$77.43M
Enterprise ValueHK$66.63M
Total Cash (Recent Filing)HK$57.82M
Total Debt (Recent Filing)HK$59.18M
Price to Earnings (P/E)41.1
Beta0.74
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding557,077,330
10 Day Avg. Volume121,000
30 Day Avg. Volume289,644
Financial Highlights & Ratios
PEG Ratio-0.41
Price to Book (P/B)0.70
Price to Sales (P/S)0.41
P/FCF Ratio2.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Operational Turnaround In 2025The company returned to small net profitability in 2025 after multi-year losses, showing the business model can generate positive earnings when margins recover. A sustained turnaround improves access to capital, reduces restructuring risk, and creates a base for scaling operations over the medium term.
Material Improvement In Cash GenerationSubstantially positive operating and free cash flow in 2025 demonstrates the business can self-fund core needs and reduces reliance on external financing. Durable cash generation supports reinvestment, deleveraging, and operational flexibility if maintained beyond a single-year rebound.
Manageable Leverage And Sizable Equity BaseA moderate debt-to-equity ratio and a sizable equity cushion provide balance-sheet flexibility to absorb shocks or fund strategic initiatives. Manageable leverage reduces near-term solvency risk and supports the company's ability to navigate industry cyclicality over the coming months.
Bears Say
Thin Net Margins And Fragile EarningsA very thin net margin offers little buffer against cost inflation, pricing pressure or demand softness. Given prior multi-year losses, persistent thin profitability raises the risk that small adverse changes could revert the company back to losses, limiting durable earnings power.
Volatile Cash Flows HistoricallyPast swings between negative and positive operating cash flow undermine predictability of free cash flow and complicate long-term planning. Volatility increases refinancing and working-capital risks and reduces confidence that the 2025 cash improvement will be sustained.
Revenue Decline And Weak Top-line TrendA falling revenue trend erodes operating leverage and makes margin gains harder to sustain. Continued top-line weakness following multi-year losses suggests demand or market-share challenges that could limit the company's ability to convert margin improvements into durable profit expansion.
Raily Aesthetic Medicine International Holdings Limited News
2135 FAQ
What was Raily Aesthetic Medicine International Holdings Limited’s price range in the past 12 months?
Raily Aesthetic Medicine International Holdings Limited lowest stock price was HK$0.10 and its highest was HK$0.20 in the past 12 months.
What is Raily Aesthetic Medicine International Holdings Limited’s market cap?
Raily Aesthetic Medicine International Holdings Limited’s market cap is HK$77.43M.
When is Raily Aesthetic Medicine International Holdings Limited’s upcoming earnings report date?
Raily Aesthetic Medicine International Holdings Limited’s upcoming earnings report date is Aug 21, 2026 which is in 91 days.
How were Raily Aesthetic Medicine International Holdings Limited’s earnings last quarter?
Raily Aesthetic Medicine International Holdings Limited released its earnings results on Mar 27, 2026. The company reported HK$0.019 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.019.
Is Raily Aesthetic Medicine International Holdings Limited overvalued?
According to Wall Street analysts Raily Aesthetic Medicine International Holdings Limited’s price is currently Overvalued.
Does Raily Aesthetic Medicine International Holdings Limited pay dividends?
Raily Aesthetic Medicine International Holdings Limited does not currently pay dividends.
What is Raily Aesthetic Medicine International Holdings Limited’s EPS estimate?
Raily Aesthetic Medicine International Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Raily Aesthetic Medicine International Holdings Limited have?
Raily Aesthetic Medicine International Holdings Limited has 557,077,330 shares outstanding.
What happened to Raily Aesthetic Medicine International Holdings Limited’s price movement after its last earnings report?
Raily Aesthetic Medicine International Holdings Limited reported an EPS of HK$0.019 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Raily Aesthetic Medicine International Holdings Limited?
Currently, no hedge funds are holding shares in HK:2135
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Raily Aesthetic Medicine International Holdings Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-15.26%
12-Months-Change
Fundamentals
Return on Equity
1.67%
Trailing 12-Months
Asset Growth
-0.48%
Trailing 12-Months
Company Description
Raily Aesthetic Medicine International Holdings Limited
Raily Aesthetic Medicine International Holdings Limited, an investment holding company, provides aesthetic medical services. The company operates through three segments: Aesthetic Medical Services, Consulting Services, and Aesthetic Medical Equipment Products. Its services include aesthetic surgery services, including aesthetic surgical procedures performed on various parts of the face or body; minimally invasive aesthetic services, primarily comprising aesthetic injection procedures; aesthetic dermatology services, such as various aesthetic energy-based procedures; and aesthetic medical management consulting services. The company also offers aesthetic dental services, including orthodontics, and dental implant and whitening; and trades in medical equipment. In addition, it sells surgical implants and aesthetic medical skincare products. The company owns and operates a network of four private for-profit aesthetic medical institutions in Zhejiang and Anhui Province, the People's Republic of China. It serves individual retail clients and aesthetic medical institutions. The company was founded in 2008 and is headquartered in Hangzhou, the People's Republic of China. Raily Aesthetic Medicine International Holdings Limited operates as a subsidiary of Ruide Consultation Limited.
Raily Aesthetic Medicine International Holdings Limited (2135) Earnings & Revenues
Technical Analysis
Beauty Farm Medical & Health Industry, Inc.
―
MediNet Group Ltd.
―
Medicskin Holdings Ltd.
―
Republic Healthcare Limited
―
RMH Holdings Limited
―